Afatinib is effective in treating squamous lung cancer in some patients, thus leading to prolonged survival and improved quality of life. Afatinib is a potent inhibitor targeting two tyrosine kinases, and is currently used as a second-line treatment for advanced squamous lung cancer, suitable for patients with advanced squamous lung cancer that has progressed despite treatment with two chemotherapy regimens. Clinical studies have confirmed that patients who are effectively treated with afatinib can bring about improvements in quality of life as well as prolonged survival. Afatinib is a second-generation oral targeted drug, after using it, skin rash, gastrointestinal adverse reactions such as diarrhea, anorexia, liver and kidney toxicity and other side effects often occur, so it is recommended that patients visit hospitals and be guided by professional doctors, and should not choose to use the drug on their own.